Sumitomo Dainippon Pharma Co., Ltd.
49 articles about Sumitomo Dainippon Pharma Co., Ltd.
Drawbridge Health Announces Partnerships to Fuel Expansion in Japan
Drawbridge Health, a healthcare technology company redefining the blood draw experience for both patients and healthcare providers, announced a further investment from Sumitomo Dainippon Pharma Co., Ltd. as well as a new research and development collaboration agreement.
Sumitomo Dainippon Pharma Oncology to Present New Data Evaluating Investigational Agent Dubermatinib at ESMO 2020 Virtual Annual Congress
Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that new data evaluating the oral investigational agent dubermatinib (TP-0903), an AXL kinase inhibitor, will be presented at the European Society of Medical Oncology (ESMO) 2020 Virtual Annual Congress, being held September 19
Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program
Collaboration to Focus on Rare Genetic and Demyelinating Diseases, Including Lysosomal Storage Diseases
BehaVR Partners to Advance Virtual Reality for Social Anxiety Disorder
BehaVR , a leading innovator of virtual reality digital wellness and digital therapeutics experiences, today announced that it has begun a new partnership aimed at leveraging virtual reality experienc
Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger of Tolero and Boston Biomedical
Sumitomo Dainippon Pharma Oncology Is Positioned to Advance Meaningful Therapies for Patients with Cancer through Innovative Drug Discovery, Research and Development
Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.
Top Biopharma M&As in 2019
1/10/2020The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
Sumitovant Biopharma Created and Launched as Sumitomo Dainippon Pharma and Roivant Sciences Close Transaction for Strategic Alliance
Sumitomo Dainippon Pharma and Roivant Sciences complete strategic alliance and formation of new company, Sumitovant Biopharma, a wholly owned subsidiary of Sumitomo Dainippon Pharma
Sumitovant will run as a wholly owned subsidiary of Sumitomo Dainippon Pharma.
Poxel and Sumitomo Dainippon Pharma Announce Positive Topline Phase 3 Results from TIMES 2 Trial of Imeglimin for the Treatment of Type 2 Diabetes in Japan and Successful Completion of the Pivotal TIMES Clinical Development Program
POXEL SA and Sumitomo Dainippon Pharma Co., Ltd announced positive topline results from TIMES 2, a Phase 3 trial evaluating Imeglimin in combination with approved hypoglycemic therapies, and as a monotherapy, for the treatment of type 2 diabetes in Japan.
The Roivant-Sumitomo Deal: $3 Billion, 5 Companies, $550 Million in Loans and an Option on 6 More...
11/1/2019The agreement was formally signed yesterday.
Urovant Sciences Secures Substantial Financial Commitment, Commercial Infrastructure Support and Minority Shareholder Protections from Sumitomo Dainippon Pharma Upon Close of Sumitomo Dainippon Pharma’s Transaction with Roivant Sciences
Sumitomo Dainippon Pharma has committed to provide an initial $200 million, low-interest, interest-only, five-year term loan facility, with no repayments due until the end of the term
Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance
Alliance will include Roivant's ownership interests in Myovant, Urovant, Enzyvant, Altavant, and Spirovant, a new company focused on developing innovative gene therapies for cystic fibrosis
Myovant Sciences Enters Landmark Agreement with Sumitomo Dainippon Pharma to Secure Major Financial Backing and Safeguards for Minority Shareholders
Sumitomo Dainippon Pharma to provide Myovant Sciences with a $350 million, low-interest, five-year term loan facility, with no repayments due until the end of the term
Sumitomo Dainippon Pharma and Roivant Sciences Enter into a Memorandum of Understanding to Create Broad Strategic Alliance to Deliver Promising New Medicines to Patients
Parties have entered into a non-binding memorandum of understanding ("Memorandum"); a definitive agreement expected by the end of October 2019
Boston Biomedical, Inc. Announces Update on Phase 3 CanStem111P Study of Napabucasin in Patients with Metastatic Pancreatic Cancer Following Interim Analysis
Boston Biomedical, Inc. announced that the CanStem111P study evaluating the safety and efficacy of investigational agent napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma will be discontinued due to futility.
Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 3) in Japan for the Treatment of Type 2 Diabetes
Imeglimin in combination with insulin Phase 3 TIMES 3 16-week, double-blind, placebo-controlled, randomized part of the trial met its primary endpoint with a favorable safety and tolerability profile
Sumitomo Dainippon Pharma Adopts Veeva Vault RIM to Streamline Global Regulatory Submissions
Leading Japanese pharmaceutical company standardizes on Vault Submissions and Vault Submissions Archive to speed submission development and health authority correspondence
Sunovion Announces Positive Top-Line Results from Pivotal Study Evaluating Dasotraline in Adults with Binge Eating Disorder
Study met its primary endpoint demonstrating fewer binge days per week with dasotraline versus placebo in the treatment of adults with moderate to severe binge eating disorder.
Poxel Announces Completion of Patient Enrollment for TIMES 1 Trial in the Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan
Japanese New Drug Application submission for Imeglimin targeted in 2020.